Working through two subsidiaries, life sciences giant Bayer is taking multiple shots at Parkinson’s disease. In addition to Bayer’s efforts to tackle Parkinson’s, Adhera Therapeutics announced that the company will acquire a new class of drug aimed at the disease.

Researchers at the University of Helsinki identified a molecule called BT13 that potentially can increase levels of dopamine.

Seven months after Prevail Therapeutics launched, the New York-based company secured $75 million in Series A financing to support the development of gene therapies for Parkinson’s disease and other neurodegenerative diseases.